Menu Search
Equities

Corbus Pharmaceuticals Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CRBP:NAQ

Corbus Pharmaceuticals Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.56
  • Today's Change-0.270 / -3.45%
  • Shares traded94.09k
  • 1 Year change-20.25%
  • Beta2.8668
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Corbus Pharmaceuticals Holdings Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 44.60m to a smaller loss of 40.21m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-49.34%
Return on equity-55.65%
Return on investment-55.11%
More ▼

Cash flow in USDView more

In 2024, Corbus Pharmaceuticals Holdings Inc increased its cash reserves by 24.14%, or 3.47m. Cash Flow from Financing totalled 166.58m or -- of revenues. In addition the company used 41.79m for operations while cash used for investing totalled 121.31m.
Cash flow per share-5.48
Price/Cash flow per share--
Book value per share7.35
Tangible book value per share7.35
More ▼

Balance sheet in USDView more

Corbus Pharmaceuticals Holdings Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio6.31
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.